Paracrine inhibition of osteoblast differentiation induced by neuroblastoma cells

The aim of our study was to investigate whether the defective function of osteogenic cells induced by neuroblastoma might play a role in the development of skeletal metastases. This mechanism has been extensively demonstrated for multiple myeloma, in which the blockage of osteoblast differentiation has been ascribed to the inhibitors of canonical Wingless pathway (Wnt), namely Dickkopf 1 (Dkk1). Our purpose was to verify if neuroblastoma cells derived from bone marrow metastases (SH‐SY5Y, LAN1) or primaries (NB100, CHP212) hamper the differentiation of mesenchymal stem cells (hMSCs) into osteoblasts in a paracrine manner, and to test whether this ability depends on Dkk1 activity. We found that all neuroblastoma cells increased the proliferation of hMSCs collected from pediatric‐aged donors, with a corresponding decrease in osteoblast differentiation markers, including alkaline phosphatase (ALP), analyzed as gene expression, enzymatic activity and number of ALP‐positive colony forming units, osteoprotegerin (OPG) release, OPG and osteocalcin gene‐expression. Dkk1 mRNA and protein were detectable in all cell lines, and the use of neutralizing anti‐Dkk1 antibody reversed the effects induced by SH‐SY5Y cells. Taken together, our results confirm that neuroblastoma hinders osteoblastogenesis, and that Dkk1 release seems to play a crucial role in blocking the differentiation of osteoprogenitor cells, though the ability to promote osteoclast activation remains an essential requirement for the development of skeletal metastases. Finally, our findings suggest that strategies regulating Wnt signaling and Dkk1 activity could be considered for adjuvant therapies in neuroblastoma metastasizing to the skeleton. © 2008 Wiley‐Liss, Inc.

[1]  D. Prockop,et al.  The Wnt Signaling Inhibitor Dickkopf-1 Is Required for Reentry into the Cell Cycle of Human Adult Stem Cells from Bone Marrow* , 2003, Journal of Biological Chemistry.

[2]  N. Baldini,et al.  Plasma levels of receptor activator of nuclear factor‐κB ligand and osteoprotegerin in patients with neuroblastoma , 2006, International journal of cancer.

[3]  S. Bruder,et al.  Growth kinetics, self‐renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation , 1997, Journal of cellular biochemistry.

[4]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[5]  A. Donfrancesco,et al.  Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Riggs,et al.  The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. , 2000, Endocrinology.

[7]  D. Prockop,et al.  How Wnt Signaling Affects Bone Repair by Mesenchymal Stem Cells from the Bone Marrow , 2005, Annals of the New York Academy of Sciences.

[8]  F. Zhan,et al.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. , 2003, The New England journal of medicine.

[9]  B. Komm,et al.  Wnt signaling and osteoblastogenesis , 2007, Reviews in Endocrine and Metabolic Disorders.

[10]  S. Hettmer,et al.  Low complex ganglioside expression characterizes human neuroblastoma cell lines. , 2005, Cancer letters.

[11]  J. Chirgwin,et al.  Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases , 2006, Clinical Cancer Research.

[12]  H. Shimada,et al.  Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. , 2005, Cancer research.

[13]  Jindrich Cinatl,et al.  Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. , 2006, International journal of oncology.

[14]  O. Sezer,et al.  Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. , 2005, Biochemical and biophysical research communications.

[15]  L. Papucci,et al.  In vitro blockade of receptor activator of nuclear factor‐κB ligand prevents osteoclastogenesis induced by neuroblastoma cells , 2004, International journal of cancer.

[16]  Chiara Brignole,et al.  Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. , 2006, Journal of the National Cancer Institute.

[17]  K. Neville,et al.  Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Hans Clevers,et al.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. , 2005, Developmental cell.

[19]  P. Schiller,et al.  Age‐Related Osteogenic Potential of Mesenchymal Stromal Stem Cells from Human Vertebral Bone Marrow , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  Roland Baron,et al.  BMP‐2 Controls Alkaline Phosphatase Expression and Osteoblast Mineralization by a Wnt Autocrine Loop , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  R. Marchelli,et al.  Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis , 2005, Molecular Cancer Therapeutics.

[22]  J. Chirgwin,et al.  Meeting report from skeletal complications of malignancy IV , 2006 .

[23]  Brendan F Boyce,et al.  Biology of RANK, RANKL, and osteoprotegerin , 2007, Arthritis research & therapy.

[24]  H. Shimada,et al.  Mechanisms of bone invasion and metastasis in human neuroblastoma. , 2005, Cancer letters.

[25]  K. Ozono,et al.  Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. , 2001, Cancer research.

[26]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[27]  S. Janz,et al.  Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF , 2007, Molecular Cancer.

[28]  C. Crews,et al.  Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. , 2003, The Journal of clinical investigation.

[29]  J. Adams Development of the proteasome inhibitor PS-341. , 2002, The oncologist.

[30]  Ivan Lobov,et al.  Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor , 2002, The Journal of cell biology.